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Redundant Parasympathetic and Sympathoadrenal Mediation of Increased 
Glucagon Secretion During Insulin-Induced Hypoglycemia in Conscious Rats 
Peter J. Havel, Susan J. Parry, Judith S. Stern, Jones 0. Akpan, Ronald L. Gingerich, 
Gerald J. Taborsky, Jr, and Donald L. Curry 
Both the parasympathetic and sympathoadrenal inputs to the pancreas can stimulate glucagon release and are activated during 
hypoglycemia. However, blockade of only one branch of the autonomic nervous system may not reduce hypoglycemia-induced 
glucagon secretion, because the unblocked neural input is sufficient to mediate the glucagon response, ie, the neural inputs are 
redundant. Therefore, to determine if parasympathetic and sympathoadrenal activation redundantly mediate increased 
glucagon secretion during hypoglycemia, insulin was administered to conscious rats pretreated with a muscarinic antagonist 
(methylatropine, n = 7), combined o- and 6-adrenergic receptor blockade (tolazoline + propranolol, n = 5), or adrenergic 
blockade + methylatropine (n = 7). Insulin administration produced similar hypoglycemia in control and antagonist-treated 
rats (25 to 32 mg/dL). In control rats (n = 9). plasma immunorea~ive glucagon (IRG) increased from a baseline level of 125 * 11 
to 1,102 f 102 pg/mL during hypoglycemia (AIRG = +977 -+ 98 pg/mL, P < .0005). The plasma IRG response was not 
significantly altered either by methylatropine (AIRG = t677 rt: 141 pg/mL) or by adrenergic blockade (AIRG = +I,374 k 314 
pgfmL). However, the IRG response to hypoglycemia was reduced to 26% of the control value by the combination of adrenergic 
blockade + methylatropine (AIRG = t250 1 83 pg/mL, P c .Ol v control rats). These results suggest that the plasma glucagon 
response to hypoglycemia in conscious rats is predominately the result of autonomic neural activation, and is redundantly 
mediated by the parasympathetic and sympathoadrenal divisions of the autonomic nervous system. 
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I 
T HAS BEEN WELL ESTABLISHED that activation of 
three different autonomic inputs to the pancreas can 
stimulate glucagon secretion. For example, activation of the 
parasympathetic nput to the pancreas by electrical stimula- 
tion of the vagal nerve trunks increases pancreatic glucagon 
release in a number of species.‘~? In addition, simulating the 
activation of the adrenal medulla by epinephrine (EPI) 
infusion stimulates glucagon secretion.3,4 Lastly, activation 
of the local sympathetic innervation of the pancreas by 
electrical stimulation also increases pancreatic glucagon 
secretion5.‘j The activation of each of these autonomic 
inputs to the pancreas has been demonstrated in response 
to hypoglycemia. Thus, activation of pancreatic parasympa- 
thetic nerves has been demonstrated during hypoglycemia 
by measuring increased secretion of the vagally sensitive 
islet hormone, pancreatic polypeptide (PP).‘** Activation of 
sympathetic nerves innervating the adrenal medulla results 
in an increase of circulating EPI.9s10 Activation of the direct 
sympathetic neural input to the pancreas during hypoglyce- 
mia has been assessed by the increased spillover of norepi- 
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nephrine (NE) from sympathetic nerves into the pancreatic 
venous effluent.r1.12 
Although autonomic activation has been demonstrated 
to contribute to increased glucagon secretion in response to 
a number of physiological stressors,13.r4 it has been more 
difficult to demonstrate a definitive role for the autonomic 
nervous system in mediating glucagon responses during 
hypoglycemia, because hypoglycemia can also directly in- 
crease glucagon secretion in the absence of autonomic 
neural activation. For example, decreasing the perfusate 
glucagon concentration can increase glucagon release from 
isolated isletsi or perfused pancreas preparations.i6 In 
addition, a number of studies, mostly conducted in human 
subjects, found no significant effect of various pharmacologi- 
cal or physical disruptions of autonomic activation on 
glucagon responses to insulin-induced hypoglycemia.17-?o 
Therefore, the prevailing view has been that a low plasma 
glucose concentration at the level of the islet, not auto- 
nomic nervous system activation, is the predominant stimu- 
lus for increased glucagon secretion during hypoglycemia. 
However, other studies designed to investigate the contri- 
bution of the autonomic nervous system, versus the direct 
effects of decreased plasma glucose concentrations, have 
demonstrated a significant autonomic component to hypo- 
glycemia-induced glucagon secretion in calveszl dogs,22 and 
mice.23 These studies are characterized by the use of 
pharmacological or surgical approaches that interrupt all 
three autonomic inputs to the A cell. Thus, it was proposed 
that during hypoglycemia, the parasympathetic and sympa- 
thoadrenal inputs to the pancreas may function in a 
redundant manner such that blockade or ablation of one or 
a portion of one autonomic subdivision is not sufficient to 
attenuate the glucagon response.24 Accordingly, atropine 
administration or surgical vagotomy,r7 administration of 
adrenergic antagonists,r8 adrenalectomy,” or sympathec- 
tomyzO alone do not reduce glucagon responses to insulin- 
induced hypoglycemia. However, if the neural control is 
redundant, then simultaneous blockade or ablation of the 
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~~r~i~~~~a~~~~~~~ adrenal m~duIla~~ and direct sympa- 
thetic inputs to the pancreas would be required to reveal 
the ful1 a~ltonomic ontribution to the glucagon response to 
hypoglycemia, 
Therefore, to determine if parasympathetic and sympa- 
thoxdrenai mechanisms can redundantly mediate increased 
giutagon secretion during hypogIy~em~a, weexamined gfu- 
c:rgrm responses to insuIi~-induced hypoglycemia in con- 
scious rats treated with the muscarinic receptor antagonist 
n~ethylatr~~pine, with a ~ol~bination of CY- and ~-adrenergic 
receptor blockers, or with both muscarinic and combined 
adrzrergic btnckade together. These responses were com- 
pared with those measured in controf, sabne-pretreated 
mts. Plasma PP and plasma catecholamine responses to 
hypoglycemia were measured as indices of parasympathetic 
and sympatiloadrenal activation, respectively. 
Adult male Sprague-Dawley rats (390 to 510 g) were used for 
these studies. Rats were individually housed in polycarbonate 
cages and fed a stock diet (Ralston Purina, St Louis, MO) and 
water ad libitum. The light-dark cycle was 12 hours on and 12 hours 
otf. with lights on at 6 AM. To access mixed venous blood, each 
animal had a silicon jugular catheter (ID. 0.3 mm, OD 0.6 mm, 
Am&can Scientific, McGraw Park, IL} implanted in the right 
atrium via the right jugular vein under pentobarbital anesthesia (65 
ttj 8) mgikg intraperitoneally), as previously described.” Catheters 
were: flushed with heparinized saline (50 UlmL) and capped when 
not .n use. Following catheter implantation, aminimum of 72 hours 
uas allowed for recovery before experiments were conducted. The 
animal preparation and experimental protocols were approved by 
the institutional animal use and care committee. and were con- 
duced in accordance with the National Institutes of Health Guide 
for 1 he Use and Care of Laboratory Animals. 
All animals were fasted overnight before the experiments, which 
ner: conducted between 11 AIM and 4 PM. In the control rats, saline 
( I mL/kg) was administered intravenously. A second group of rats 
reef ived atropine methyl bromide 10 mgikg (Sigma Chemical, St 
Louis, MO) intravenously. Atropine methyl bromide was used 
r&l-er than atropine sulfate because a&opine methyl bromide does 
not readity cross the blood-brain barrier?’ and thus should not 
impair central nervous system muscarinic, cholinergic neurotrans- 
mission. A third group received a combination of a B-adrenergic 
blocker, propranolol HCI (1 mgikg. Inderal. Ayerst Laboratories, 
New York, NY), and an n-adrenergic blocker, tolazoline HCI (10 
mg/ kg. Priscoline, Ciba-Geigy, Summit, NJ). The dose of proprano- 
1111 exceeds that which has been demonstrated to s~gnificant~ 
impair ~ardi(~v~ls&uiar reflexes in ratsZh Tolazoline was adminis- 
tered at a dose five to 10 times the dose (per kg) reported to 
pro&ce significant cr-adrenergic blockade in humansZ7 Lastly, 
both muscarinic blockade (methylatropine) and combined adrener- 
gic llockade (propranolol + tolazoline) were induced in a fourth 
grottp of rats. Fifteen minutes after administration of saline or 
~~ut(~nomic antagonists, baseline samples were drawn from the 
jugt,lar cannuta. Then 1.0 to 2.0 U/kg regular porcine insulin (Eli 
L ill;/ and Co. Indianapolis, IN) was administered intravenously as a 
bolus. A second blood sample was drawn 30 minutes following the 
inst_lin injection. After each blood sample was drawn, an equal 
volume of heparinized blood (20 UlmL) cottected from donor rats 
was replaced via the jugular cannula. 
Blood samples for glucose and PP determinati[~n were placed in 
tubes containing ERTA. Blood samples for ca~e~holarnj~~ determi- 
nation were placed in tubes containing EGTA and reduced 
glutathione. Blood samples for determination of immuIloreactive 
glucagon (1RG)were placed in tubes containing heparin and 50 FL 
aprotinin (24 TXUimL). All samples were kept on ice until 
C~Iltr~fugation (2,SOO rpm for 20 minutes at 4°C). The plasma was 
then decanted and frozen at -20°C until assayed. 
Plasma glucose was assayed by the glucose oxidase method with 
a glucose analyzer (Beckman Instruments, Fullerton, CA). The 
plasma ~mmunoreactive PP level was measured ~d~~~imn~unolog~- 
caiiy in unextracted plasma with a guinea pig-derived antisera, as 
previously described.zs Plasma NE and EPI levels were measured 
in duplicate with a sensitive and specitic radioen~matic assay.“’ 
The plasma IRCi level was measured according to the method of 
Faloona and Unger by radiojmmu~oassay with an antibody that 
has a high degree of specificity for the CUOH-terminal portion of 
the glucagon molecute.sO The range of the standard curve is 0 to 
2,000 pg/mL. Intxaassay and interassay coefficients of variation for 
the glucagon assay in this laboratory are 11% and l2?is. respec- 
tively. 
The changes of plasma glucose, PP, NE, EPI, and IRG in Tables 
1 through 5 were calculated by subtracting the O-minute baseline 
value from the 30-minute value following the injection of insulin. 
The percentage data in Figs I through 4 were calculated by dividing 
the change of IRG in individual rats by the mean change of IRG in 
the control animals x 100. Data are expressed as the mean it SE. 
Statistical comparisons of means within a group were made with a 
paired f test. For statistical comparisons of means of different 
groups, ANOVA was performed with a Dunn&t‘s post-test. 
Plasma Ghtcase 
RESULTS 
Baseline plasma glucose averaged 100 r 3 mg/dL in 
control rats, and decreased by 71 L 2 mg/dL to a mean of 
29 c 2 mg!dL. Baseline plasma glucose Ievels, the glucose 
level 30 minutes after insulin administration. and the 
plasma glucose decrement did not differ significantly from 
control values in any of the groups of animals treated with 
autonomic antagonists (Table 1). 
Ptasma PP 
Plasma PP increased more than sevenfold during insulin- 
induced hypoglycemia (Table 2). Plasma PP was also 
significantly increased during hypoglycemia in atropixrized 
Table 1. Baseline Plasma Glucose Concentrations and Glucose 
Levels During IIH 
Plasma Glucose img/dL) 
WI 30 f JO 
Treatment Baseline Mlnutes Minutes 
.-_- 
Control (n = 9) 100 % J 29 c 2 -71 + 2 
Methylatropine (n = 7) 105 rt 4 J2 fr 2 -73 rt 5 
Acirenergic blockade (n = 5) 90 * 6 29 c 3 -61 5 5 
Methylatropine + adrenergic 
blockade (n = 7) 91 Cd 25 t 2 -66 I4 
NOTE. Values are the mean c SEM. 
Abbreviation: IIH, insulin-induced hypoglycemia. 
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Table 2. Baseline PP Concentrations and PP Responses During IIH 
IIH 30 330 
Treatment Baseline Minutes Minutes 
Control (n = 9) 29 + 3 276 + 46 t247 + 46t 
Methylatropine (n = 7) 27 % 2 112 + 24 t85 + 24*t 
Adrenergic blockade (n = 5) 48~9 228k36 +179-c36t 
Methylatropine + adrenergic 
blockade In = 7) 39 + 6 66 + 7 t26 ? 7*t 
NOTE. Values are the mean + SE. 
Abbreviation: IIH, insolin-induced hypoglycemia. 
*P < .Of vcontrol. 
tf < .Ol v baseline. 
rats, but this response was reduced by approximately 6.5% 
and was significantly smaller than the response in control 
rats (P < .Ol). The increase of plasma PP during hypoglyce- 
mia in rats treated with both (Y- and B-adrenergic antago- 
nists was not signi~cantly different from the response in 
control rats. In rats that received both methylatropine and 
combined adrenergic blockade, the response was signifi- 
cantly reduced compared with that in control rats (P < .Ol; 
Fig 1, Table 2). 
CONTROL ATROPINE AOR. BLOCK BOTH 
Plasma NE and EPI 
Fig 2. Plasma NE responses 30 minutes after insulin injection as a 
percentage of the mean control response to insulin-induced hypogly- 
cemia in conscious rats. Animals received either saline (CONTROL, 
n = 9). methylatropine 10 mg/kg (ATROPINE, n = 7). tolazoline 10 
mg/ kg + propranolol 1 mg/ kg (ADR. BLOCK, n = 5), or methylatro- 
pine + adrenergic antagonists (EOTH, n = 7). l P < .Ol v CONTROL. 
Absolute plasma NE levels are provided in Table 3. 
Baseline NE was increased in rats that received adrener- 
gic antagonists or methylatropine and adrenergic antago- 
nists together. Plasma NE increased during hypoglycemia 
in all four groups of rats, but the increase of NE was 
significantly larger in animals that received adrenergic 
blockers alone than in the control animals (Fig 2, Table 3). 
Baseline EPI Ievels were also increased in rats that received 
adrenergic blockade or methylatropine plus adrenergic 
blockade; however, the increase of EPI during hypoglycemia 
was similar in all four groups of animals (Fig 3, Table 4). 
PlASmA IRG 
In control rats, plasma IRG was increased by nearly 
eightfold during insulin-induced h~o~ycemia (P < .0005; 
Table 5). The increases of plasma IRG in rats pretreated 
with methylatropine or the (Y- and P-adrenergic antagonists 
were not significantly different from the response in control 
animals. The plasma IRG response in rats that received 
both methylatropine and adrenergic antagonists was re- 
duced to 25% of that in the control rats (P < .Ol; Fig 4, 
Table 5). 
CONTROL ATROPINE AVR. BLOCK BOTH 
Fig 1. Plasma PP responses 30 minutes after insulin injection as a 
percentage of the mean control response to insulin-induced hypogly- 
cemia in conscious rats. Animals received either saline (CONTROL, 
n = S), methylatropine 10 mg/kg (ATROPINE, n = 7), tolaroline 10 
mglkg + propranolol 1 mglkg (ADR. BLOCK, n = 51, or methylatro- 
pine + adrenergic antagonists (BOTH, n = 7). *P < .Ol v CONTROL. 
Absolute plasma PP levels are provided in Table 2. 
DISCUSSION 
Activation of both parasympathetic and sympathoadre- 
nal inputs to the pancreas during hypoglycemia has been 
Table 3. Baseline NE Concentrations and NE Responses During IIH 
NE bg/mL) 
IIH 30 9 30 
Treatment Baseline Minutes Minutes 
Control (n = 9) 210 _f 30 1,560 + 230 + 1,350 -t 230t 
Methylatropine 
(n = 7) 350 * 30 1,650 + 80 + 1,300 2 80t 
Adrenergic blockade 
@I = 5) 1,430 2 410* 4,040 2 1,050 +2.610 i 710*t 
Methylatropine + 
adrenergic 
blockade (n = 7) 1,210 2 250* 2,870 r 420 + 1,660 2 450t 
NOTE. Values are the mean ? SE. 
Abbreviation: IIH, insulin-induced hypoglycemia. 
*P < .Ol v control. 
tP < .05 v baseline. 
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CONTROL ATROPINE ADR. BLOCK BOTH 
Fig 3. Plasma EPI responses 30 minutes after insulin injection as a 
percentage of the mean control response to insulin-induced hypogly- 
cemia in conscious rats. Animals received either saline (CONTROL, 
n = S), methylatropine 10 mg/kg (ATROPINE, n = 7), tolazoline 10 
mg, kg + propranolol 1 mglkg (AM. BLOCK, n = 5) or methylatro- 
pine + adrenergic antagonists (BOTH, n = 7). Absolute plasma EPI 
levels are provided in Table 4. 
demonstrated. This study was designed to determine if the 
parasympathetic and sympathoadrenal divisions of the 
autonomic nervous system redundantly contribute to in- 
creased pancreatic glucagon secretion during hypoglycemia 
in conscious rats. Although the effects of parasympathetic 
and sympathoadrenal activation on numerous physiological 
parameters are often antagonistic, during hypoglycemia the 
activation of either major autonomic subdivision has a 
sirrilar result-increased giucagon secretion. However, for 
redundancy between these systems to exist, selective block- 
adr: of either the parasympathetic or sympathoadrenal 
inputs to the pancreas should not significantly reduce the 
glucagon response to insulin-induced hypoglycemia, but 
blockade of both autonomic divisions together must result 
in it substantial reduction of the glucagon response. There- 
fore, in the present study, hypoglycemia was induced by 
insulin injection in four groups of chronically cannulated 
Table 4. Baseiine EPI Concentrations and EPI Responses During IIH 
EPI ipg/mLl 
IIH 30 A30 
Treatment Baseline Minutes Minutes 
.- 
Gontroi (n = 9) 130 2 40 7,570 rt- 1,170 +7,440 + 1,150t 
Mrthylatropine 
rrl = 7) 200 r 30 11,220 t 1,430 +11,020 t 1.420t 
Acrenergic blockade 
tn = 5) 590 +- 140* 10,190 t 760 +9,600 ? 820t 
Methylatropine + 
#rdrenergic 
blockade (n = 7) 970 % 200* 9,940 rf: 1,990 +8,970 f 1.890t 
NOTE. Values are the mean 2 SE. 
Abbreviation: IIH, insulin-induced hypoglycemia 
‘P s. ,025 “control. 
tP c .Ol v baseline. 
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Table 5. Baseline IRG Concentrations and IRG Responses During IIH 
IRG lpg/mLi 
IIH 30 _! 30 
Treatment Baseline Minutes Minutes 
Control (n = 9) 125 % 11 1,102 i 102 1-977 i 98t 
Methylatropine 
hl = 71 183 2 30 861 +_ 739 1677 rt 141t 
Adrenergic blockade 
in = 5) 153~8 1,260 t_ 209 +-I,707 + 202t 
Methylatropine i 
adrenergic 
blockade (n = 7) 262 c 55* 512 ri 55 +250 ‘r 83”t 
NOTE. Values are the mean ? SE. 
Abbreviation: IIH, insulin-induced hypoglycemia. 
*P < .Ol Y control. 
tP < .Ol Y baseline. 
conscious rats, ie, control saline-treated rats and rats 
pretreated either with the muscarinic antagonist methylat- 
ropine to impair the effects of parasympathetic neural 
activation, with a combination of CY- and P-adrenergic 
receptor antagonists to impair the effects of adrenal medul- 
lary and sympathetic neuronal activation. or with both 
methy~atropine and adrenergic antagonists together. 
Insulin administration produced similar hypoglycemia 
and similar decrements of plasma glucose in all four groups 
of animals. Thus, the glucopenic stimulus at the brain and 
at the islet was comparable between treatments. As a result 
of this central neuroglucopenia, plasma PP levels were 
markedly increased both in the control rats and in the rats 
pretreated with adrenergic antagonists, demonstrating an 
increase of the parasympathetic vagal input to the islet in 
these animals. Plasma levels of PP have been used as an 
indirect index of activation of the par~isympathetic, cholin- 
4 
, __--_____ ._-.- 
I / 
CONTROL ATROPINE ADR. BLOCK BOTH 
Fig 4. Plasma IRG responses 30 minutes after insulin injection as a 
percentage of the mean control response to insulin-induced hypogly 
cemia in conscious rats. Animals received either saline (CONTROL, 
n = 9), methylatropine 10 mglkg (ATROPINE, n = 7), toiazoline 10 
mg/ kg + propranolol 1 mg/kg (ADR. BLOCK, n = 5) or methylatro- 
pine + adrenergic antagonists (BOTH, n = 7). *P c .Ol v CONTROL. 
Absolute plasma IRG levels are provided in Table 5. 
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ergic input to the islet. 7,8 Accordingly, plasma PP responses 
were reduced by 65% to 90% in rats that received methyl- 
atropine or methylatropine plus adrenergic antagonists, 
suggesting that pancreatic cholinergic receptor activation 
was substantially reduced in these animals. 
Plasma EPI levels were increased during hypoglycemia in 
ail rats, reflecting increased adrenal medullary secretion of 
this sympathetic neuroho~one. The increase of plasma 
NE during insulin-induced hypoglycemia in rats is primarily 
the result of neuronal NE release rather than of NE 
secretion from the adrenal medulla,31 and therefore, in- 
creased plasma NE levels indicate increased spillover from 
sympathetic nerve terminals. Plasma catecholamine re- 
sponses to hypoglycemia would not be expected to be 
reduced by adrenergic blockade, as the PP response is by 
atropine, because adrenergic antagonists block the action 
and not the release of EPI and NE. In fact, pretreatment of 
rats with the adrenergic antagonists propranolol and tolazo- 
line increased baseline plasma levels of both NE and EPI. 
Plasma NE, but not EPI responses to insulin-induced 
hypoglycemia were also increased by adrenergic blockade. 
Increased baseline and hypoglycemia-stimulated plasma 
NE levels may result from an action of the c-w-adrenergic 
antagonist to block presynaptic al-receptors that inhibit 
neurotransmitter release from sympathetic nerves.3Z In- 
creased baseline EPI may be due to blockade of P-adrener- 
gic receptors that are involved in the clearance of plasma 
EPI.“s Alternatively, adrenergic receptor blockade could 
result in increased basal or hypoglycemia-stimulated plasma 
catecholamines if the blockade produced significant hypo- 
tension. Since blood pressure was not measured in this 
study, it is not known what degree of hypotension may have 
resulted from administration of the adrenergic blockers. 
Pharmacological blockade of peripheral parasympa- 
thetic, muscarinic receptors with methylatropine in con- 
scious rats did not significantly reduce the increase of 
plasma glucagon during insulin-induced hypoglycemia com- 
pared with the response observed in control animals. 
Although it is possible that a statistically significant effect of 
methylatropine to reduce the glucagon response to hypogly- 
cemia would have been found if larger numbers of animals 
were used, this effect would likely be small because at least 
70% of the glucagon response was intact in these animals. 
This result conflicts with a previous study conducted in 
anesthetized rats in which atropine partially reduced the 
glucagon response to insulin-induced hypoglycemia.s4 How- 
ever, in that experiment, atropine rather than methylatro- 
pine was used. Since atropine more readily crosses the 
blood-brain barrier,25 it is uncertain whether the activation 
of central cholinergic receptors is also impaired after 
atropine administration. We have found that atropine 
sulfate does significantly reduce the glucagon response to 
insulin-induced hypoglycemia in conscious rats (unpub- 
lished observations), in contrast to the lack of effect of 
methylatropine reported in the present study. In human 
duodenal-ulcer patients with truncal vagotomy, the gluca- 
gon response to insulin-induced hypoglycemia was signifi- 
cantly reduced compared with the response in control 
subjects.35 However, other studies in human subjects found 
that neither a&opine administration nor vagotomy reduced 
the glucagon response to insulin-induced hypoglycemia 
when compared with responses observed in control sub- 
jects,17 suggesting that selective interruption of the parasym- 
pathetic input to the islet alone is not always sufficient to 
impair glucagon responses to hypoglycemia. 
Similar to methylatropine-treated animals, the glucagon 
response to hypoglycemia in rats treated with the fy- and 
@-adrenergic antagonists tolazoline and propranolol was 
not significantly different from the response in control rats. 
In a previous study, it was observed that combined adrener- 
gic blockade did not impair the glucagon response to 
insulin-induced hypoglycemia in anesthetized rats.j6 An- 
other study showed no reduction of glucagon responses to 
hypoglycemia in adrenodemedullated rats that were also 
chemically sympathectomized with reserpine.j7 A similar 
lack of effect of combined adrenergic blockade’” or func- 
tional sympathoadrenalectomy2” on hypoglycemia-induced 
glucagon responses has been reported in human subjects. 
Functional adrenale~tomy, produced by diverting adrenal 
venous blood from the systemic irculation, did result in an 
impaired glucagon response to insulin-induced hypoglyce- 
mia in pentobarbital-anesthetized dogs.38 However, pento- 
barbital anesthesia abolishes the activation of cholinergic 
input to the islet during central neuroglucopenia in dogs.‘” 
Therefore, both paras~pathetic and adrenal medullary 
inputs to the A celf would be expected to be diminished 
under these experimental conditions. Thus, selective impair- 
ment of sympathoadrenal activation or its effects does not 
usually result in decreased glucagon responses to hypoglyce- 
mia. 
Administration of both methylatropine and adrenergic 
antagonists together before insulin injection reduced the 
glucagon response to hypoglycemia to 25% of that observed 
in control animals. Therefore, simultaneous blockade of 
both parasympathetic, muscarinic and sympathoadrenal 
adrenergic receptors reveals that autonomic neural activa- 
tion makes a major contribution to h~oglycemia-induced 
glucagon secretion in conscious rats. This result is compat- 
ible with results from previous experiments in which the 
administration of ganglionic blocking agents, which impair 
both parasympathetic and sympathoadrenal neural activa- 
tion, eliminates the majority of the glucagon response to 
insulin-induced hypoglycemia in dogs22 and mice.“” Simi- 
larly, the combination of vagotomy and surgical sympathoad- 
renalectomy markedly reduces the glucagon response to 
hypoglycemia in dogs.” In addition, the selective infusion 
of glucose into the carotid and vertebral arteries Supplying 
the brain in order to prevent central neuroglucopenia in 
conscious dogs reduces both parasympathetic and sympa- 
thoadrenal activation and eliminates the glucagon response 
to insulin-induced hypoglycemia.~ 
In the present study, methylatropine and combined 
adrenergic blockade together prevented the majority of the 
glucagon response to hypoglycemia; however, a significant 
portion (25%) of the response persisted despite the block- 
ade. This portion of the glucagon response could be a direct 
result of low plasma glucose concentrations at the level of 
the islet.‘“,14 In addition to a possible direct effect, low 
NEURAL CONTROL OF GLUCAGON DURING HYPOGLYCEMIA 
plasma glucose levels may potentiate neurally mediated 
glucagon secretion, since it is likely that in the absence of 
hypoglycemia utonomic activation would be a less potent 
stimulus for glucagon release. Thus, both low islet glucose 
concentrations and autonomic activation may be required 
fol full expression of the glucagon response. Alternatively, 
it s possible that parasympathetic neuropeptides such as 
vasoactive intestinal polypeptide or sympathetic neuropep- 
Tides such as galanin contribute to the portion of the 
ghcagon response that was not blocked by atropine and 
combined adrenergic blockade. Both vasoactive intestinal 
polypeptide and galanin stimulate glucagon secretion41xJ2 
anj are released from the pancreas during electrical stimu- 
lation of parasympathetic or sympathetic nerves, respec- 
iiv:ly. -’ 4344 In addition, it has recently been shown that 
gaianin is co-released with NE from pancreatic sympathetic 
ne-ves during insulin-induced hypoglycemia in dogs.” The 
XI ions of these neuropeptides would not be expected to be 
blocked by the classic muscarinic and adrenergic receptor 
<m:agonists. 
n human subjects, administration of a ganglionic block- 
mg agent, which would impair both parasympathetic and 
kympathoadrenal ctivation, significantly reduced glucagon 
r-esponses to insulin-induced hypoglycemia.45 However, in 
antIther study, administration of atropine and adrenergic 
an .agonists together did not alter the glucagon response to 
hypoglycemia,Jh suggesting that autonomic activation may 
no: contribute to hypoglycemia-induced glucagon secretion 
m humans. Alternatively, noncholinergic, nonadrenergic 
mechanisms (peptides) could contribute to glucagon re- 
sponses to hypoglycemia in human subjects after administra- 
tion of classic muscarinic and adrenergic blockers. 
‘Together, the results of this study provide evidence to 
xupport the hypothesis that parasympathetic and sympa- 
t hoadrenal autonomic activation mediate glucagon re- 
sponses to hypoglycemia in a redundant fashion, such that 
lnt-rfering with either autonomic subdivision alone will not 
Im3air the glucagon response in rats. There is some 
experimental evidence from other species that supports this 
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idea. For example, in anesthetized dogs, it was found that 
neither bilateral vagotomy nor surgical sympathectomy 
alone affected plasma glucose recovery after insulin admin- 
istration, but that both procedures together produced a 
marked impairment of plasma glucose rccovery.37 Unfortu- 
nately, plasma glucagon levels were not measured in this 
study; however, since increased glucagon secretion is the 
primary mechanism for recovery of plasma glucose from 
insulin-induced hypoglycemia, 48.4y this study provides indi- 
rect support for the redundancy hypothesis. More direct 
evidence is provided by the observation that atropine or 
splanchnic-nerve transection delayed or modestly reduced 
glucagon responses to hypoglycemia in conscious calves, 
whereas atropine and splanchnic-nerve transection to- 
gether markedly impaired the glucagon response.” Therc- 
fore, redundancy between the major autonomic subdivi- 
sions, if unrecognized, could lead to underestimation of the 
autonomic contribution to hypoglycemia-induced glucagon 
secretion. 
In summary, neither methylatropinc nor combined LY- 
and P-adrenergic blockade alone alter the glucagon re- 
sponse to insulin-induced hypoglycemia in conscious rats, 
but methylatropine and adrenergic blockade together elimi- 
nate 75% of this response. Thus, activation of the auto- 
nomic nervous system is responsible for the majority of the 
glucagon response to hypoglycemia in rats, and this re- 
sponse can be redundantly mediated by either parasympa- 
thetic or sympathoadrenal neural activation. 
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